they should be ready for the first human trial in 2025, results on xenograft prostate cancer models have been excellent
“The ability of cancer to hack the iron metabolism pathways is an important driver of tumour growth and spread, and a means by which cancers can overcome the effects of treatment. Our lead peptide candidate, FT-002a, holds exciting potential to enhance the effectiveness of cancer therapy and improve the health and wellness of cancer patients”